Paying user area
Try for free
Thermo Fisher Scientific Inc. pages available for free this week:
- Income Statement
- Statement of Comprehensive Income
- Common-Size Income Statement
- Analysis of Profitability Ratios
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Dividend Discount Model (DDM)
- Return on Equity (ROE) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Thermo Fisher Scientific Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
| P/S | = | Share price1, 2, 3 | ÷ | Sales per share1 | Sales per share1 | = | Revenues1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 29, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 29, 2008 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 2, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Thermo Fisher Scientific Inc. Annual Report.
The price-to-sales (P/S) ratio exhibited considerable fluctuation between 2006 and 2026. Initially, the ratio increased from 2.15 in 2006 to a peak of 5.05 in 2007, before declining to 2.40 in 2008. A subsequent drop to 1.44 occurred in 2009, followed by a period of relative stability and gradual increase through 2014, reaching 3.74. From 2014 through 2018, the P/S ratio continued to climb, peaking at 4.01. The period between 2018 and 2021 saw further increases, culminating in a high of 5.52 in 2021. A slight decrease to 5.39 was observed in 2022, followed by a more pronounced decline to 4.73 in 2023 and 4.34 in 2026.
- Overall Trend
- The P/S ratio demonstrated an overall upward trend over the twenty-year period, despite several intermediate declines. The ratio more than doubled from 2006 to 2021, indicating increasing investor willingness to pay for each dollar of sales. However, the most recent years (2022-2026) suggest a potential stabilization or modest correction in this valuation.
- Volatility
- Significant volatility is apparent, particularly in the earlier years of the observed period (2006-2009). This suggests sensitivity to market conditions or company-specific events during those times. The period from 2010-2017 exhibited lower volatility, indicating a more stable valuation. The recent decline from 2021-2026 introduces renewed volatility.
- Relationship to Share Price and Sales per Share
- The P/S ratio is a product of share price and sales per share. Increases in the ratio were often driven by increases in both components, although share price generally had a more substantial impact. For example, the large increase in the P/S ratio in 2021 coincided with a significant increase in share price. The recent decline in the P/S ratio from 2022-2026 appears to be influenced by both a decrease in share price and a slower growth rate in sales per share.
- Peak and Trough Values
- The highest P/S ratio was recorded in 2021 at 5.52, while the lowest was in 2009 at 1.44. These represent the extremes of valuation during the analyzed period. The substantial difference between these values highlights the dynamic nature of investor sentiment and market conditions.
Comparison to Competitors
| Thermo Fisher Scientific Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | ||||||||||||
| Feb 20, 2025 | ||||||||||||
| Feb 22, 2024 | ||||||||||||
| Feb 23, 2023 | ||||||||||||
| Feb 24, 2022 | ||||||||||||
| Feb 25, 2021 | ||||||||||||
| Feb 26, 2020 | ||||||||||||
| Feb 27, 2019 | ||||||||||||
| Feb 28, 2018 | ||||||||||||
| Feb 28, 2017 | ||||||||||||
| Feb 25, 2016 | ||||||||||||
| Feb 26, 2015 | ||||||||||||
| Feb 27, 2014 | ||||||||||||
| Feb 27, 2013 | ||||||||||||
| Feb 29, 2012 | ||||||||||||
| Feb 24, 2011 | ||||||||||||
| Feb 26, 2010 | ||||||||||||
| Feb 27, 2009 | ||||||||||||
| Feb 29, 2008 | ||||||||||||
| Mar 1, 2007 | ||||||||||||
| Mar 2, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Thermo Fisher Scientific Inc., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Thermo Fisher Scientific Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 26, 2026 | ||
| Feb 20, 2025 | ||
| Feb 22, 2024 | ||
| Feb 23, 2023 | ||
| Feb 24, 2022 | ||
| Feb 25, 2021 | ||
| Feb 26, 2020 | ||
| Feb 27, 2019 | ||
| Feb 28, 2018 | ||
| Feb 28, 2017 | ||
| Feb 25, 2016 | ||
| Feb 26, 2015 | ||
| Feb 27, 2014 | ||
| Feb 27, 2013 | ||
| Feb 29, 2012 | ||
| Feb 24, 2011 | ||
| Feb 26, 2010 | ||
| Feb 27, 2009 | ||
| Feb 29, 2008 | ||
| Mar 1, 2007 | ||
| Mar 2, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
| Thermo Fisher Scientific Inc. | Health Care | |
|---|---|---|
| Feb 26, 2026 | ||
| Feb 20, 2025 | ||
| Feb 22, 2024 | ||
| Feb 23, 2023 | ||
| Feb 24, 2022 | ||
| Feb 25, 2021 | ||
| Feb 26, 2020 | ||
| Feb 27, 2019 | ||
| Feb 28, 2018 | ||
| Feb 28, 2017 | ||
| Feb 25, 2016 | ||
| Feb 26, 2015 | ||
| Feb 27, 2014 | ||
| Feb 27, 2013 | ||
| Feb 29, 2012 | ||
| Feb 24, 2011 | ||
| Feb 26, 2010 | ||
| Feb 27, 2009 | ||
| Feb 29, 2008 | ||
| Mar 1, 2007 | ||
| Mar 2, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).